Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Liver Cirrhosis

  Free Subscription


25.05.2020

2 Am J Pathol
1 Gut
3 Hepatology
2 J Hepatol
1 PLoS One
2 Z Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Pathol

  1. ZHOU Z, Kim JW, Qi J, Eo SK, et al
    Toll-Like Receptor 5 Signaling Ameliorates Liver Fibrosis by Inducing Interferon beta-Modulated IL-1 Receptor Antagonist in Mice.
    Am J Pathol. 2020;190:614-629.
    PubMed         Abstract available

  2. PETRESCU AD, Grant S, Williams E, Frampton G, et al
    Coordinated Targeting of Galanin Receptors on Cholangiocytes and Hepatic Stellate Cells Ameliorates Liver Fibrosis in Mdr2-Knockout Mice.
    Am J Pathol. 2020 Jan 14. pii: S0002-9440(20)30003.
    PubMed         Abstract available


    Gut

  3. QI X, Liu Y, Wang J, Fallowfield J, et al
    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
    Gut. 2020 May 20. pii: gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666.
    PubMed        


    Hepatology

  4. LI W, Li Y, Siraj S, Jin H, et al
    FUNDC1-mediated mitophagy suppresses hepatocarcinogenesis by inhibition of inflammasome activation.
    Hepatology. 2018 Jul 27. doi: 10.1002/hep.30191.
    PubMed         Abstract available

  5. HLADY RA, Sathyanarayan A, Thompson JJ, Zhou D, et al
    Integrating the Epigenome to Identify Novel Drivers of Hepatocellular Carcinoma.
    Hepatology. 2018 Aug 22. doi: 10.1002/hep.30211.
    PubMed         Abstract available

  6. INZAUGARAT ME, Johnson CD, Holtmann TM, McGeough MD, et al
    NLRP3 inflammasome activation in hepatic stellate cells induces murine liver fibrosis.
    Hepatology. 2018 Sep 4. doi: 10.1002/hep.30252.
    PubMed         Abstract available


    J Hepatol

  7. CHAN HL, Wong VW, Yip TC, Wong GL, et al
    Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30273.
    PubMed        

  8. SONNEVELD MJ, Brouwer WP, de Man RA
    Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page?
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30231.
    PubMed        


    PLoS One

  9. SIRINAWASATIEN A, Techasirioangkun T
    Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    PLoS One. 2020;15:e0229517.
    PubMed         Abstract available


    Z Gastroenterol

  10. SEBODE M, Kloppenburg A, Aigner A, Lohse AW, et al
    Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment.
    Z Gastroenterol. 2020;58:431-438.
    PubMed         Abstract available

  11. ZHELEGU I, Ebert MP, Vogelmann R
    [Current standard of antibiotic prophylaxis in esophageal varices bleeding in Germany].
    Z Gastroenterol. 2020;58:445-450.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: